GC Cell signs contract with UCI Therapeutics for CAR-NK therapy development

[Courtesy of GC Cell]

South Korean biomedical company GC Cell has signed a contract development and manufacturing organization (CDMO) deal with UCI Therapeutics for chimeric antigen receptor-natural killer (CAR-NK) cell and gene therapies, the company announced on Wednesday.

Founded in 2020, UCI Therapeutics is a bio-venture company that develops CAR-NK immunotherapy based on NK cell engineering technology.

CAR-NK is a cell therapy that combines chimeric antigen receptor (CAR), which specifically targets cancer cells, with natural killer (NK) cells.

Under the contract, GC Cell will be responsible for the manufacturing, storage, and quality testing of UCI Therapeutics’ pipeline products. It will also handle some process development.

“Through this partnership, we aim to leverage each other’s capabilities in biopharmaceutical research, development, and manufacturing to create synergies,” said GC Cell Chief Executive Officer James Park.